 WARREN, N.J., Dec. 01, 2020 GLOBE NEWSWIRE -- Bellerophon Therapeutics, Inc. Nasdaq: BLPH Bellerophon or the Company, a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the first patient has been enrolled in its REBUILD Phase 3 registrational clinical study evaluating INOpulse, a pulsed inhaled nitric oxide therapy, as a potential treatment for fibrotic interstitial lung disease fILD. 